We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients on GLP-1s for type 2 diabetes had a lower ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 agonists and co-agonists conferred better ...

"This is the first GLP-1 receptor agonists study to show significant reduction in the risk of kidney failure…Our study establishes GLP-1 receptor agonists as an important kidney-protective class of ...

Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related cancers more than insulin did. Use of the drug class was also linked to a ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences. Review: ...

About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, according to a research letter published online Dec. 10 in JAMA Surgery.